Foreign-Trade Zone (FTZ) 5-Seattle, Washington; Authorization of Production Activity; Juno Therapeutics, Inc. (Biopharmaceuticals), Bothell, Washington
---
identifier: "/us/fr/2021-12808"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 5-Seattle, Washington; Authorization of Production Activity; Juno Therapeutics, Inc. (Biopharmaceuticals), Bothell, Washington"
title_number: 0
title_name: "Federal Register"
section_number: "2021-12808"
section_name: "Foreign-Trade Zone (FTZ) 5-Seattle, Washington; Authorization of Production Activity; Juno Therapeutics, Inc. (Biopharmaceuticals), Bothell, Washington"
positive_law: false
currency: "2021-06-17"
last_updated: "2021-06-17"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2021-12808"
document_type: "notice"
publication_date: "2021-06-17"
agencies:
- "Commerce Department"
- "Foreign-Trade Zones Board"
fr_citation: "86 FR 32247"
fr_volume: 86
docket_ids:
- "B-12-2021"
---
# Foreign-Trade Zone (FTZ) 5—Seattle, Washington; Authorization of Production Activity; Juno Therapeutics, Inc. (Biopharmaceuticals), Bothell, Washington
On February 12, 2021, Juno Therapeutics, Inc., submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 5C, in Bothell, Washington.
The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the *Federal Register* inviting public comment (86 FR 11921, March 1, 2021). On June 14, 2021, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including Section 400.14.
Dated: June 14, 2021.
Andrew McGilvray,
Executive Secretary.